ArticleCellular & molecular biology letters2023
Human umbilical cord mesenchymal stem cell exosome-derived miR-874-3p targeting RIPK1/PGAM5 attenuates kidney tubular epithelial cell damage.
Article in Cellular & molecular biology letters, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 75 citations in OpenAlex.
- Necroptosis and the RIPK1-RIPK3-MLKL pathway in chronic kidney disease: mechanisms, crosstalk, and therapeutic opportunities.Renal failure · 2026Review
- Mitochondrial quality control in health and disease: Updates 2026.Chinese medical journal · 2026Review
- HucMSC-EVs attenuate renal fibrosis via miR-874-3p-mediated inhibition of cGAS-STING signaling.Cell biology and toxicology · 2026Article
- Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes Attenuate Renal Fibrosis by Suppressing Fibroblast Activation via the INHBA/PI3K/AKT Pathway.Pediatric discovery · 2026Article
- Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes Ameliorates Testicular injury to improve spermatogenic disorder through PRDX1/TRAF6/TGFβ signaling pathway.Clinical and experimental medicine · 2026Article
- Human urine-derived stem exosomes inhibit inflammation and oxidative stress in sepsis-related acute kidney injury.BMC molecular and cell biology · 2026Article
- Mesenchymal stem cell-derived extracellular vesicles: emerging cell-free therapeutics for kidney diseases.Frontiers in immunology · 2026Review
- Research progress of exosomes in renal ischemia-reperfusion injury.Frontiers in pharmacology · 2026Review
- Exosome Augmentation Technologies for Drug Delivery and Disease Treatment: A Review.Biomaterials research · 2026Review
- Effects of Shenkang for chronic kidney disease: a propensity score matched with network pharmacology analysis.Renal failure · 2025Article
- Exosomes derived from human umbilical cord mesenchymal stem cells ameliorate AKI after cardiac surgery by facilitating miR-21-5p targeting TEAD1.Renal failure · 2025Article
- Intermittent fasting triggers interorgan communication to improve the progression of diabetic osteoporosis.Gut microbes · 2025Article
- Cisplatin-induced acute kidney injury is alleviated by BMSCs-derived exosome via mmu-miR-874-3p-mediated activation of the wnt/β-catenin signaling pathway.Regenerative therapy · 2025Article
- Isolated Monoclonal Human Urine-Derived Stem Cells Showed Differential Therapeutic Effects on Renal Ischemia-Reperfusion Injury in Mice.Biomedicines · 2025Article
- Non-Protein-Coding RNA and Acute Kidney Injury: New Developments from Pathogenesis to Potential Biomarker.Genes · 2025Review
- Article
- Stem cell-derived exosomes in complicated urinary tract infections: immunomodulatory mechanisms and potential therapeutic strategies for urothelial repair.Stem cell research & therapy · 2025Review
- Mesenchymal stem cell-derived exosomes as a potential therapeutic strategy for ferroptosis.Stem cell research & therapy · 2025Review
- Emerging Frontiers in acute kidney injury: The role of extracellular vesicles.Bioactive materials · 2025Review
- HucMSCs-Derived Extracellular Vesicles Deliver RPS27A Protein to Manipulate the MDM2-P53 Axis and Ameliorate Neurological Dysfunction in Parkinson's Disease.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundKidney insults due to various pathogenic factors, such as trauma, infection, and inflammation, can cause tubular epithelial cell injury and death, leading to acute kidney injury and the transformation of acute kidney injury to chronic kidney disease. There is no definitive treatment available. In previous studies, human umbilical cord mesenchymal stem cells have been shown to promote kidney injury. In this preclinical study, we investigate the role and mechanism of human umbilical cord mesenchymal stem cell exosomes (HucMSC-Exos) on the repair of renal tubular epithelial cells after injury.
methodsC57BL/6 mice underwent unilateral ureteral obstruction, and epithelial cell injury was induced in HK-2 cells by cisplatin. HucMSC-Exos were assessed in vivo and in vitro. The extent of renal cell injury, activation of necroptosis pathway, and mitochondrial quality-control-related factors were determined in different groups. We also analyzed the possible regulatory effector molecules in HucMSC-Exos by transcriptomics.
resultsHucMSC-Exo inhibited necroptosis after renal tubular epithelial cell injury and promoted the dephosphorylation of the S637 site of the Drp1 gene by reducing the expression of PGAM5. This subsequently inhibited mitochondrial fission and maintained mitochondrial functional homeostasis, mitigating renal injury and promoting repair. In addition, HucMSC-Exo displayed a regulatory role by targeting RIPK1 through miR-874-3p.
conclusionThe collective findings of the present study demonstrate that HucMSC-Exos can regulate necroptosis through miR-874-3p to attenuate renal tubular epithelial cell injury and enhance repair, providing new therapeutic modalities and ideas for the treatment of AKI and the process of AKI to CKD transformation to mitigate renal damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.